The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
April 22nd 2025
The in vivo gene editing program is designed to eliminate cccDNA and inactive integrated hepatitis B DNA.
Cardinal Health Specialty Solutions Launches PathWare Decision Support Transaction Solutions
May 29th 2012Cardinal Health Specialty Solutions today launched PathWare Decision Transaction Solutions, a new technology system that makes it easier for payors and physicians to work together to implement programs that improve the quality and cost of caring for patients.
Read More
Regulatory Authorities Accept Oral BG-12 Marketing Applications For Review
May 11th 2012Biogen Idec recently announced that United States and European Union regulatory authorities have accepted the company's marketing applications for the review of BG-12 (dimethyl fumarate), an oral therapeutic candidate for the treatment of multiple sclerosis (MS).
Read More
FDA Issues Alert on Unproven Treatment for Multiple Sclerosis
May 10th 2012The Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).
Read More
H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
May 8th 2012H.D. Smith, among the nation's largest pharmaceutical wholesalers, recently announced a 3-year prime vendor agreement with PharmacyGPO, a buying group that services independent community pharmacies across the United States.
Read More
Walgreens Adds 6 Medications to Oral Oncology Clinical Program
May 3rd 2012Walgreens Specialty Pharmacy is adding 6 medications to its oral oncology cycle management program, in a significant expansion of the comprehensive treatment and support program it provides to benefit patients, physicians and payers.
Read More
FDA Approves Afinitor for Treatment of Non-Cancerous Kidney Tumors
April 30th 2012Novartis Pharmaceuticals Corporation announced that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.
Read More
FDA Approves Votrient for Advanced Soft Tissue Sarcoma
April 27th 2012The United States Food and Drug Administration approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.
Read More